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Introduction: 
Chemists are constantly searching for solutions to various problems and one of the 
solutions that has become popular to turn to is the nanoparticle. A nanoparticle is defined as a 
particle with dimensions between 1 and 100 nanometers. These tend to be surrounded by an 
interfacial layer that plays an integral part in the properties of the particles. Nanoparticle 
chemistry gained momentum in the 1980s and has become a major topic in the chemical research 
field. Many uses have been found for nanoparticles as they offer unique variability. The ability to 
control the size, shape, exterior composition and cargo make them ideal solutions for many 
problems. They have been used to help stabilize food emulsions,1 create vaccinations,2 and clean 
up water produced from fracking.3 One of the major fields that has been greatly expanding is the 
department of nanomedicine. Since nanoparticles are small enough to travel throughout various 
parts of the cell, they accumulate well within cells. Much of the current research in nanoparticles 
is directed toward the use of nanoparticles for cancer treatment, prevention and imaging. 
Cancer is a set of diseases in which abnormal cells divide without control and have the 
ability to invade nearby tissues.4 Most of the popular treatments used today involve 
organometallics, immunotherapy and radiation. One of the most common and well known 
treatments is an organometallic known as cisplatin.5 This treatment makes use of a platinum-
based compound to destroy cancer cells, but a common problem is getting treatments such as this 
to the cancer cells. Nanoparticles offer a unique tunability that makes them great carriers for 
cancer treatments that can surpass some of the many obstacles within the body and deliver the 
treatment to the desired cancer cells. Nanoparticles can be used in imaging, prevention and 
treatment of cancer. The four nanoparticles that will be examined here have been developed for 
one or more of these three uses. 
Iron Oxide Nanoparticle for Use as a Magnetic Resonance Contrast Agent 
 Superparamagnetic iron oxide nanoparticles (SPION) have been a topic of interest for 
many chemists within the cancer related nanoparticle field. This is because of the potential that 
has been displayed in applications such as drug delivery, therapy, and magnetic resonance 
imaging (MRI).6 The common contrast agents required for MRI are gadolinium-based. SPION 
has the potential to replace these gadolinium-based contrast agents as they may offer a higher 
enhancement of imaging. The direct use of SPION as an MRI contrast agent results in the 
formation of aggregates within the blood plasma and are quickly removed by macrophages.7 
Macrophages are a type of white blood cell that digests foreign substances within the body. This 
problem with SPION seems to be caused by the high surface-to-volume ratio and the forces 
between the nanomagnetites. The hope of Lee, et al. was to engineer a SPION with a surface that 
could minimize the aggregation of the particles within normal physiological conditions.8 
 Various polymers have been used to modify the surface of the SPION to increase their 
ability to function in vivo. Poly(ethyleneglycol)s (PEG) has been widely used with success, but 
there is concern about the stability of the PEG coat in physiological conditions since the PEG 
coating has typically been achieved through noncovalent interactions between the PEG and the 
surface of the nanoparticle. To correct for this concern, Lee, et al. took the approach of forming 
polymeric monolayers of PEG-silane copolymers via covalent bonds to the SPION. The 
copolymer used was poly(TMSMA-r-PEGMA). This is a randomized copolymer synthesized 
from (trimethoxy silyl)propyl methacrylate and PEG methacrylate.9 Adding the copolymer to the 
SPION created a poly(TMSMA-r-PEGMA)-coated SPION or poly(TMSMA-r-
PEGMA)@SPION.8 
 To produce the polymer-coated SPION, two methods can be used. The iron oxide core is 
formed and separated while the polymer is being added or the polymer is added after the core 
nanoparticle is formed. The former version was labeled as “in situ” (IS) and the latter as 
“stepwise” (SW). Lee, et al. produced the coated SPION through both methods and examined 
results to determine which method was better for the desired outcome. They found that the IS-
SPION created smaller sizes and lower magnetization. The SW method produced the needed size 
of the SPION with higher magnetization levels. In both methods, polymer coating resulted in the 
hydrophilic PEG being present at the outer surface of the SPION as desired. The hydrolyzed 
silane formed multiple covalent bonds at the surface of the magnetite. Cross-linkage between 
silane groups of the polymer chains resulted in hardening of the layers of copolymers. The 
representation of the poly(TMSMA-r-PEGMA)@SPION is shown in Figure 1.8 
 
Figure 1: A representation of the polymer-coated SPION and the chemical structure of 
the poly(TMSMA-r-PEGMA) are depicted.8 
 To examine the formation of the poly(TMSMA-r-PEGMA)@SPION, Fourier transform 
infrared spectroscopy (FTIR) was used. Spectra were taken for both the IS-SPION and the SW-
SPION. The spectra, found in Figure 2, showed peaks around 1720, 1105, and 627 cm-1 that 
correspond to a carbon to oxygen double bond, carbon to oxygen single bond, and a silicone to 
oxygen single bond, respectively. These bonds are some of the identifiable aspects that confirm 
the presence of the poly(TMSMA-r-PEGMA) attached to the SPION.8 
 
Figure 2: The Fourier transform infrared spectroscopy results of both the (a) IS-SPION 
and (b) SW-SPION are shown with important peaks labeled with the corresponding 
bonds.8 
 Thermogravimetric analysis (TGA) was used to reveal that the weight percentage of the 
poly(TMSMA-r-PEGMA) was 45% for IS-SPION and 30% for the SW-SPION. Dynamic light 
scattering (DLS) measurements showed narrow size distributions for both SPIONs. This means 
that there is uniformity within the nanoparticles and that production seems to create SPIONs in a 
consistent manner. Transmission electron microscopy (TEM) images indicate that the core size 
of the SW-SPION is greater than that of the IS-SPION. From this information and the results 
from the DLS, it can be concluded that the SW-SPION has a thinner coating of the polymer 
layers than the IS-SPION. This corresponds with the data from the TGA.8 
 As mentioned before, the method for creating the IS-SPION can cause lower 
magnetization because of the interference of the polymer in the crystallization step of iron oxide 
nanoparticles. When testing the magnetic moment of both nanoparticles, it was found to agree 
with this hypothesis as the SW-SPION showed a larger magnetic moment than the IS-SPION. 
The magnetic moment measured for the SW-SPION was larger than any previously reported 
polymer-coated SPION of this size. This is one potential advantage of the SW method over the 
IS coating method.8 
 Stability tests needed to be conducted before the research went any farther. The SPION 
were investigated in phosphate buffered saline (PBS) over a broad pH range to mimic 
physiological conditions. Neither SPION showed aggregation in the pH range from 1 to 10 over 
a span of 1 month. The naked SPION exhibited aggregation within the first hour. This implies 
that the polymer coating allowed the SPION to remain suspended in aqueous media.8 
 Another aspect of the SPION that Lee, et al. investigated was the uptake of the 
nanoparticles by macrophages. Cell uptake experiments were run using a macrophage cell line. 
To detect the presence of SPION within the cells, Prussian blue staining was performed after 2 
hours. The SPION uptake was compared to Feridex I.V., a common MRI contrast agent. The 
uptake of Feridex I.V. was high and most of the cells were blue after the staining. IS- and SW-
SPION showed a significantly lower amount of uptake by the cells. This can be seen by the low 
amount of blue staining in the cells in Figure 3. The decreased uptake of the IS- and SW-SPION 
seems to indicate that the polymer coating layer in this system is able to greatly minimize the 
recognition by macrophages.8  
 
Figure 3: Prussian blue staining images of a macrophage cell line are depicted. (a) The 
control cells with no blue staining are shown. (b) The cells treated with Feridex are 
shown to contain high levels of Prussian blue. (c) Cells treated with IS-SPION and (d) 
those treated with SW-SPION both show low levels of Prussian blue.8 
 The toxicity of the poly(TMSMA-r-PEGMA)@SPION was then examined within the 
Lewis lung carcinoma (LLC) cell line by performance of an MTT assay. Even at high 
concentrations, the SPION shows no toxicity. The tests were ran using concentrations as high as 
100 μg of iron per mL. This concentration is much higher than those needed for conventional 
SPION-based MRI contrast agents. The use of the poly(TMSMA-r-PEGMA)@SPION should be 
a safe option for use within the body as an MRI contrast agent.8 
 Lee, et al. hypothesized that poly(TMSMA-r-PEGMA)@SPION could accumulate 
within the tumor sites by the enhanced permeability and retention (EPR) effect. This is possible 
because of the presence of leaky vasculatures in and around tumors. The increased 
hyperpermeability allows the SPION to be brought into the tumor. This hypothesis was tested by 
subcutaneous injection of the LLC cell line into mice, followed by MR imaging of the mice at 
specific time points. The tumors were visible as hyperintense areas in the MR images found in 
Figure 4. It was found that IS-SPION were removed from tumors much faster than the SW-
SPION. This may be attributed to the smaller size of the SW-SPION. The SW-SPION allowed 
the tumor to still be visible for up to 4 hours after injection, with all of the nanoparticle removed 
from the tumor site after 11 hours. Some nanoparticle accumulation occurred within the kidneys 
but was gone within a day. This would seem to indicate that the SPION is able to be removed 
from the system in a way that should not allow any harm to be done.8 
  
Figure 4: MR images taken at 0,1 and 4 hours post injection using IS-SPION (a, b, and c) 
and SW-SPION (d, e, and f).8 
 Prussian blue staining of the tumors was also performed to identify any accumulation of 
iron oxide within the tumor areas. Larger amounts of iron oxide were present within the tumors 
of the mice that had been injected with the SW-SPION than in the mice injected with IS-SPION. 
This matches the results of the MR images. The staining and MR images show that the 
poly(TMSMA-r-PEGMA)@SPION is able to successfully target the tissue from tumors to allow 
for cancer imaging and diagnosis.8 
 The poly(TMSMA-r-PEGMA)@SPION work as antifouling nanoparticles to be used for 
cancer imaging and diagnosis. These nanoparticles showed in vivo magnetic resonance imaging 
capabilities and can potentially be used as a cancer diagnostic method. The SPION were able to 
enter tumor tissues directly via the EPR effect and resist uptake by macrophages. The targeting 
efficacy of these magnetic nanoprobes could potentially be increased by attaching specific 
targeting ligands onto the surface. Further research can be done into this and the ability to 
replicate these results in larger organisms.8 
pH-Responsive Metal Organic Framework Nanoparticles Used for Treatment 
Protein therapy has arisen as a great potential treatment for various diseases. The design 
and delivery of the proteins are typically challenging as they are poor at permeating the cell 
membrane and are susceptible to denaturation. Scientists have begun integrating proteins with 
molecules that have a greater ability to penetrate cell membranes and protect them from 
degradation.10 The problems associated with any of the past polymeric capsules used for protein 
transport are the loading efficiency and capacity limiting the effectiveness for therapeutic use 
and the high level of removal by phagocytes. 
Cheng, et al., introduced the concept of a biomimetic nanosystem that encapsulates 
proteins in a metal organic framework (MOF) nanoparticle camouflaged by an extracellular 
vesicle membrane (EVM) as depicted in Figure 1. The desire was to encapsulate the protein in a 
MOF that would allow for intracellular release. An EVM would then be added to protect the 
MOF and protein from phagocytes.  
 
Figure 5: A schematic that illustrates the approach used to create the biomimetic EMP 
nanoparticle used for targeting tumors and delivering anticancer proteins into the cells.11 
 The MOF used is the zeolitic imidazolate framework-8 (ZIF-8). Cheng, et al., used the 
ZIF-8 matrix to encage proteins by the assembly of metal nodes of Zinc ions with 2-
methylimidazole.11 The MOF of this complex is pH-responsive as the metal-ligand bonds release 
the proteins in an acidic environment. This makes it possible for the MOF to release the proteins 
within endosomes or lysosomes in cells. The internal surface area of the MOF-protein (MP) 
nanoparticles is large, and this, in combination with the noncovalent affinity, allows a high 
amount of protein to be loaded within it. The loading efficiency is about 94%.11  
 The protein cargo is enveloped by the ZIF-8 nanoparticles by self-assembly as an 
aqueous solution, while adjusting the concentration of the ligands and proteins to optimize the 
diameter and morphology of the MP nanoparticles. Various proteins were able to be 
encapsulated in MP nanoparticles without altering the crystal structure or morphology of the 
MOF. The major factors that impacted whether a protein caused a change in the morphology 
were the isoelectric points and the molecular weight. To test the ability of the MP nanoparticles 
to encapsulate the proteins, Fourier transform infrared spectroscopy (FTIR) was used. Peaks 
around 1667 cm-1 were observed if the proteins were absorbed by the MOF as this would 
indicate a carbon to oxygen double bond. The spectra presented in Figure 6 show the FTIR 
results from the protein the MOF and the MP separately. The arrow points to the peak present in 
the spectra for the MP that matches the needed 1667 cm-1. The pore size of the MOF helps stop 
proteases from gaining access to the encaged proteins.  
 
Figure 6: Fourier transform infrared spectroscopy results from the protein, MOF, and MP 
are shown. An arrow points to the key bond used to confirm the encapsulation of the 
protein by the MOF.11 
 The MP nanoparticles were then coated in extracellular vesicles. The EVs were obtained 
from tumor cells by ultracentrifugation. The EVM is assembled around the MP nanoparticle 
surface with the assistance of ultrasonication.11 Success of this method could be partially driven 
by electrostatic and hydrophilic interactions between the EV membrane and the MOF matrix.12 
The process was optimized to where the EVM could completely cover the surface of the 
nanoparticle. Most of the content from the EV that had the chance of causing tumor metastasis 
was removed throughout the course of this procedure. The use of tumor-cell-derived EVs allows 
the preferential targeting of cancer cells from great distances within the organism. This was 
shown to be true by testing the EMP nanoparticle that had an EVM derived from MDA-MB-231 
tumor cells on various cell lines. The uptake of the EMP nanoparticles by the MDA-MB-231 
cells exhibited an uptake efficiency about 2- to 8-fold higher than the other cells tested.11 
 The stability of the EMP nanoparticles was then tested. Dynamic light scattering, a 
technique commonly used for determining particle size and size distribution studies,13 was used, 
as well as TEM. After three days, there was no significant change in the EMP nanoparticles. The 
stability can be attributed to the hydrophilic surface glycans of the membrane. The hydrophilicity 
allows the EMP nanoparticles to be dissolved in aqueous solutions within the body.11 
 The fate of nanoparticles within an organism is determined by the ability of the 
nanoparticles to absorb proteins. The EMP nanoparticles have been designed to have a reduced 
amount of adsorption of serum proteins. The EVM portion of the EMP nanoparticles allows for a 
reduced adsorption of serum proteins because of the hydrophilic surface glycans. This allows an 
approximately 6-fold reduction in the adsorption of proteins compared to the bare MP 
nanoparticles. Another major factor in the survival of the biomimetic nanoparticles is the ability 
to avoid internalization by macrophages. To test the EMP nanoparticles for this, fluorescence 
proteins were encapsulated in the nanoparticles and allowed to incubate in a macrophage-like 
cell line for 2 hours. Using laser scanning microscopy and flow cytometry, Cheng, et al., were 
able to see a decrease in the uptake of the proteins into the macrophage-like cells compared to 
MP nanoparticles and liposome-enveloped nanoparticles. The uptake into the macrophage-like 
cells of EMP nanoparticles was only about 30% that of the original MP nanoparticles.11 
 The uptake and intracellular release mechanisms of the EMP nanoparticles were also 
studied. One of the most common methods to allow particles into a cell is known as endocytosis. 
To study the mechanism of internalization for the EMP nanoparticles, the cells that were treated 
were also incubated in various endocytosis inhibitors. Flow cytometry results indicated that 
inhibitors dynasore and methyl-beta-cydodextrin caused the uptake of the nanoparticles to be 
greatly reduced.11 This showed that the internalization of the EMP nanoparticles happens via 
dynamin- and cholesterol-dependent endocytosis.14 The nanoparticle was wrapped inside of an 
endosome as it enters the cell. 
 Once inside of the cell, the EMP nanoparticle’s pH dropped. The addition of hydrogen 
ions into the inside of the endosome attributes for this. The decreased pH causes the MOF matrix 
to release the organic ligand of the imidazole derivative. The proteins are released inside of the 
endosome as well. This causes a buffering effect as the imidazole ring becomes protonated.11 
This cationic polymer leads to osmotic swelling of the endosome, which results in the breaking 
of the endosomal membrane and the release of the proteins into the cytosol. The mechanism 
described is known as the “proton-sponge” effect.15  
 These EMP nanoparticles then had the protein gelonin, an N-glycosidase that cleaves a 
bond in rRNA that inhibits protein synthesis, enveloped within them. This combination was then 
tested on MDA-MB-231 cells in vitro. While the MOF nanoparticles and the EVM-enveloped 
nanoparticles have no significant levels of toxicity without the protein, the EMP nanoparticles 
loaded with gelonin and the MP nanoparticles that contain gelonin show high levels of 
cytotoxicity to the cancerous cells. The EMP nanoparticle shows a half-maximal inhibitory 
concentration of about 0.025 μM. The half-maximal inhibitory value, or IC50 value, is a measure 
of the concentration that is required to inhibit 50% of the cells from growing. The smaller the 
value is, the more toxic the compound is.11 
The combination of EMP nanoparticles with gelonin was then tested on tumors in mice 
and compared to treating the tumors separately with just phosphate buffered saline solution, 
gelonin, and the MP nanoparticles. The EMP nanoparticle treated tumors showed decreased 
tumor growth compared to any of the other controls. The results can be seen in Figure 7. Mice 
were then dissected and the cells from throughout the body were examined. None of the major 
organs showed any abnormalities after being treated with any of the four options, including the 
EMP nanoparticles.  The EVM-camouflaged EMP nanoparticles can target tumor tissue and 
inhibit growth while causing minimal toxicity in other major organs. The EMP nanoparticles, 
loaded with an indocyanine green-labeled gelonin, accumulated at the tumor site according to 
fluorescent scans. The levels of fluorescence in other parts of the mice were detectable within the 
first 24 hours but were nonexistent after 72 hours. This shows that the nanoparticle was able to 
pass through the rest of the body and only target the cancer cells. 
 
Figure 7: Tumor growth was greatly diminished by treatment with gelonin encapsulated 
by EMP nanoparticles.11 
The EMP nanoparticle developed by all-in-one self-assembly shows high levels of 
loading efficiency combined with high cancer targeting. The ability of the EMP nanoparticle to 
deliver proteins directly to the cancerous cells due to the extracellular vesicle membrane 
camouflage is possibly translational. Using the protein gelonin as a model, Cheng, et al., were 
able to show that the EMP nanoparticles were able to deliver proteins to cancerous cells while 
going mostly undetected by the cell immune responses.11 This shows a promising use for cancer 
treatment as the EMP nanoparticles could potentially deliver proteins to any cell in the body.11 
Trimodality Imaging and Treatment Using an Upconversion Nanoparticle 
 
Figure 8: Upconversion nanoparticles work by converting NIR light into the UV. This 
can be used for diagnosis or therapy.16 
 Some nanoparticles can work as an imaging method for cancer and a treatment. One such 
nanoparticle that is being studied works for imaging cancer and is able to deliver a drug used to 
treat it. The possibility of a hybrid system that combines multiple diagnosis methods and therapy 
drugs together has become more likely with the emergence of greater nanotechnology. Different 
imaging techniques are used to diagnose cancer, but they all have limitations. For instance, MRI 
provides great spatial images but has limited sensitivity.17 Taking advantage of multiple imaging 
systems together can increase the abilities for cancer diagnosis. 
The nanoparticle studied by Dai, et al. is a trans-platinum pro-drug-conjugated 
upconversion nanoparticle.16 Upconversion luminescence (UCL) is a nonlinear optical process 
that converts low-energy photons that are in the near infrared (NIR) end of the spectrum into 
high-energy photons that are in the ultraviolet (UV), visible or NIR by the sequential absorption 
of two or more photons. This process causes a large Stokes shift and sharp emission lines.18 
Various lanthanide doped upconversion nanoparticles have been used for deep tissue imaging 
and as contrast agents for magnetic resonance imaging (MRI) and computer tomography (CT).19 
The hope of Yunlu Dai, et al. was to develop an upconversion nanoparticle-based multimodal 
imaging technology that is also able to deliver chemotherapy.16 
 Trans-Platinum(IV) complexes have been shown to be activated to higher toxic 
platinum(II) complexes by UV, green or blue light.20 The use of these shorter wavelengths of 
light are not sensible to use in vivo as these have poor penetration into the tissue and cause 
damage to healthy tissue. Dai, et al. attempted to solve these issues by creating an 
Ytterbium/Thulium-co doped upconversion nanoparticle. This nanoparticle emits UV via 
multiphoton absorption of NIR light. The hope is that the nanoparticle will be able to effectively 
be upconverted as NIR light has the deepest tissue penetration of all safe wavelengths of light.16 
The upconverted nanoparticle created by Dai, et al. has a core shell of NaYF4:Yb
3+/Tm3+ 
@NaGdF4/Yb
3+ (UCNPs) that acts as the drug carrier. This was created by a thermal 
decomposition method. The product from this step is then stabilized using polyethylenimine 
(PEI). The dicarboxyl light-activated platinum(IV) pro-drug used is trans,trans,trans-[Pt(N3)2-
(NH3)(py)(O2CCH2CH2COOH)2] (labeled as DPP). The UCNPs were enhanced with the DPPs 
being conjugated to their surface by adding the PEI-UCNPs to N-hydroxysuccinimide (NHS) 
and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). NHS is used as a 
carboxylic acid activator and EDC is a carboxyl activating agent. The UCNP-DPP was then 
coated with a layer of polyethylene glycol (PEG). The addition of PEG is used to reduce the 
possibility of evoking a response to the nanoparticles from the host’s immune system. The 
structure of the nanoparticles was confirmed using high-angle annular dark-field scanning 
transmission electron microscopy. Results from the high-angle annular dark-field scanning 
transmission electron microscopy (HAADF-STEM) show that the platinum(IV) pro-drug was 
successfully conjugated on the surface of the nanoparticles.16  
To examine whether this process worked to create the UCNP-DPP-PEGs, transmission 
electron micrographs were taken as shown in Figure 9. The UCNPs show uniform morphology 
and a size around 65 nm. The phase structure of the nanoparticles was examined using X-Ray 
diffraction. The results confirmed the structure of the nanoparticles to have a core pattern of a 
hexagonal phase structure of NaYF4. The growth of the NaGdF4 shell is shown as well. When the 
NaGdF4 increased the upconversion luminescence intensity increased remarkably. Inductively 
coupled plasma mass spectrometry (ICP-MS) was utilized to find that the platinum content of the 
nanoparticles is 26 μg per mg of UCNP-DPP-PEG.16 
 
Figure 9: Transmission electron microscope images of the oleic-acid-capped 
nanoparticles (b), core-shell structured UCNPs (c), and UCNP-DPP-PEG nanoparticles 
(d).16 
Tm3+-doped UCNPs can emit NIR light at 800 nm after excitation from a 980 nm laser. 
This emission can be used to cause the NIR-to-NIR UCL imaging as the UCNP emits in the UV, 
visible and NIR. The UCNP-DPP-PEGs were injected into tumors in mice. The UCL imaging 
confirmed that a significant signal could be produced and observed from use of the UCNP-DPP-
PEG within the tumor. The Gd3+ ions of the UCNPs cause the UCNPs to have the ability to be 
used as MRI contrast agents. The UCNP-DPP-PEG also shows a greater ability for use as a 
contrasting agent in CT imaging than the commonly used iobitridol.16  
The ability of the UCNP-DPP-PEGs to be used as a cancer treatment were also studied. 
The first investigation looked into whether the UV emission caused by the upconversion of the 
UCNPs could activate the platinum (IV) DPP. The absorption spectrum of the DPP is compared 
with the emission spectra of pure UCNPs and DPP-conjugated UCNPs with the use of a 980 nm 
laser. The decrease in the emission intensity of the UCNP-DPPs at 452 and 477 nm and the 
decrease in the UV range indicate that the DPP is being activated as shown in Figure 10a. The 
absorption spectra of the UCNP-DPP-PEG is expressed as a function of exposure time to the 980 
nm laser. This spectrum decreases in intensity at 289 nm with increased exposure time as seen in 
Figure 10b. When platinum-azide bonds break, there should be a decrease in the spectrum at 289 
nm. When the DPP is released, it is expected that there would be a loss of platinum-azide 
bonds.21 The 980nm laser effectively activates the platinum (IV) complex.16 
 
Figure 10: The absorption spectrum of the DPP and emission spectra of UCNPs and 
DPP-conjugated UCNPs are depicted after being introduced to NIR light from a 980 nm 
laser (a). The absorption spectra of the UCNP-DPP-PEG expressed as a function of time 
of exposure to 980 nm laser radiation with a highlight of the decrease at 289 nm (b).16 
ICP-MS was performed to examine the stability of the UCNP-DPP-PEGs within the 
blood. Only 30% of the platinum was released into the serum after 48 hours in the dark. The 
ability of the UCNP-DPP-PEGs to release the DPP molecules was also calculated to be roughly 
between 3000 DPP molecules per UCNP-DPP-PEG over 1 hour under a 980 nm laser. With 1 
hour of irradiation from 365 nm UV light, 10000 DPP molecules are released per particle. The 
use of the NIR light or UV can effectively cause the upconverted UV emission from the UCNPs 
to convert the platinum (IV) DPP into platinum (II) complexes. These rough calculations were 
performed based upon the absorption spectra under the NIR and UV irradiation. The ability to 
release the drug under the 980 nm NIR joined with the ability to activate the DPP to form highly 
toxic platinum (II) drugs increases the ability to kill cancer cells.16  
To test for the cytotoxicity of the UCNP-DPP-PEGs, HeLa cells were dosed with varying 
concentrations of the nanoparticles. Both the control and the cells dosed with UCNP-DPP-PEGs 
were irradiated with the 980 nm laser or the UV light. These tests showed that the DPP 
complexes can be delivered via the UCNPs to the cells and can be activated to form the more 
cytotoxic platinum (II). The DPP conjugated UCNPs are able to reduce the adverse side effects 
that are normally seen from platinum-based anticancer drugs.16 
The research presented by Dai, et al. is the first recorded example of using UCNPs as 
nanotransducers that also control trimodality imaging. These UCNPs convert the penetrating 
NIR light into UV radiation to release the anticancer drugs. The use of NIR light allows for 
activation of the UCNP-DPP-PEG at increased depths within the body and shows better tumor 
growth inhibition than using 365 nm UV radiation. Most other photodynamic therapies (PDTs) 
require a presence of oxygen to kill cancer cells. This is a problem as cancer cells tend to be 
hypoxic. The UCNP-DPP-PEG does not require the oxygen and, therefore, has a more promising 
application as a cancer therapy. Further research will be conducted by this group into the 
mechanisms of the reactions that happen in the UCNP-DPP-PEGs and into the ability to inject 
the nanoparticles intravenously.16 
Glycopolymer-Stabilized Gold Nanoparticles for Use as a Cancer Vaccine 
Another nanoparticle that has been researched recently takes a different approach to 
treating cancer. Parry, et al. worked to produce a nanoparticle-based cancer vaccine. Two types 
of cancer vaccines exist. Preventative cancer vaccines work in a similar method to the influenza 
vaccination, but the treatment cancer vaccines work as another method to attack the cancer once 
it has already formed.22 The synthesized nanoparticle investigated would work as a preventative 
vaccine to protect the patient from breast cancer.23 
Healthy mammary cells have a surface that is characterized by branched, O-linked 
glycans. These glycans have high levels of a compound called N-acetyl-ᴅ-glucosamine 
(GlcNAc). Breast cancer cells present linear, truncated mucin-type glycans. Mucin-type glycans 
are carbohydrates that form a thin layer similar to mucus. An example of the type of glycan 
present on the membrane of breast cancer cells is α-N-acetyl- ᴅ-glucosamine (αGalNAc). This 
glycan is also known as the Tn-antigen ligand.  
The hope of Parry, et al. was to create a nanoparticle that presents a surface like that of 
breast cancer cells to engage the receptors of the immune system. This would produce an 
effective vaccine. Other attempts to perform this included using peptides24, dendrimers25 and 
proteins. The alternative platform of the nanoparticle offers greater synthetic controls and 
increased density of glycans compared to any of the current scaffolds produced. Presenting the 
carbohydrates in a “multicopy-multivalent” manner on the surface of the nanoparticle should 
create a surface that mimics that of a cancerous cell.23 The “multicopy-multivalent” manner is 
simply placing the same glycan on the surface multiple times in a row to offer more locations for 
antigens or antibodies to bind.26 Figure 11 shows the reaction used to create the desired Tn 
glycan monomer with the correct stereochemistry. 
 
Figure 11: A presentation of the reaction pathway to create the glycopolymer-stabilized 
gold nanoparticles. The size of the nanoparticles produced show consistency, with a 
diameter around 9 nm.23 
 
Once the pure anomer had been created, the glycopolymers were prepared using a 
process known as Reversible Addition-Fragmentation chain Transfer (RAFT) polymerization.23 
This is a radical polymerization that uses a chain transfer agent that allows for control over the 
length of the chain and the polydispersity of the polymer.27 By varying the ratio of reactants and 
conditions, chains of various lengths and compositions were obtained. The Tn-antigen glycan 
monomer was then copolymerized with poly(ethylene glycol) methyl ether methacrylate 
(PEGMA). These polymers were then added to the gold nanoparticle via a reduction by sodium 
borohydride to form the polyTn-NPs.23 
The size of the nanoparticles was tested using dynamic light scattering and transmission 
electron microscopy. The size distribution of the particles presented diameters mostly in the 
range of 5 to 20 nm. To test the loading of the antigen and the polymer, TGA was used. The 
results indicated that longer polymer chains could be used to create smaller nanoparticles with a 
larger ratio of glycans to gold.23 
With the hope of Parry, et al. being to produce an immune response using these 
nanoparticles, tests had to be ran in vivo on New Zealand White rabbits. The rabbits were 
immunized with the polyTn-NP or free polymers at various times throughout the testing. An 
ELISA assay was performed on blood drawn from the rabbits at day 0, 42 and 70 to test for the 
number of antibodies present. The results from the rabbits that were treated with just the free 
polymers showed low or negligible responses from the immune system as very few antibodies 
were produced, as can be seen in Figure 12. All the rabbits treated with the glyconanoparticles 
had a greater concentration of antibodies present. The number of antibodies also increased as 
time went on.23  
 
Figure 12: The results of immunological experiments with the glyconanoparticles and 
glycopolymers displayed as box plots. (a) Serum antibody titers were measured using the 
enzyme-linked immunosorbent assay (ELISA). (b) The cross-reactivity of serum 
antibodies with mucins were tested via ELISA.23 
Examining the data from the ELISA assays, a relationship between the density of the 
carbohydrates and the response from the immune system can be defined. The optimum density 
can be calculated to be somewhere between 20 to 25 units per polymer chain. The reason for this 
is not fully known and must be studied further. To test for the ability of the nanoparticle 
generated antibodies to recognize naturally occurring antigens, the bovine submaxillary mucin 
glycoprotein was used. After 70 days of immunization with the glyconanoparticles, antibodies 
that were specific for the naturally occurring mucin glycans were present.23 
Parry, et al. were able to synthesize a ‘multicopy-multivalent’ nanoparticle covered in 
tumor-associated antigen glycans. The nanoparticle was shown to generate significant immune 
responses in vivo. The immune system was still able to recognize natural, healthy Tn-antigen 
glycans. This means that the nanoparticle was able to induce an immune response specifically for 
breast cancer cells.  The level of titers reported in this research are at a level lower than those 
obtained with glycoconjugates that were based on protein-toxin conjugates.28 Further research 
must be done to figure out why the levels were lower and to determine methods to increase the 
response by the immune system. 
Summary and Thoughts 
Nanoparticles offer a great option for various disease treatments. The ability to fine tune 
the nanoparticles offers exceptional variability and can deliver other chemical agents to assist as 
treatment of cells. The capability of the anticancer drug to be either encapsulated within the 
nanoparticle or part of the outer layer of the particle offers other unique opportunities. As this 
method of drug delivery is of similar size to the cells involved, this makes it easier for direct 
uptake into the cells. The ability to change the outside coating of the nanoparticle offers the 
ability to camouflage or change the targeting abilities of the nanoparticle. The makeup of the 
outer shell can also be controlled in such a way as to provide other effects similar to those 
created by the lanthanide-doping of the UCNP. Adjusting nanoparticles allow for greater ability 
for them to be used for cancer imaging, prevention and treatment.  
Cancers vary greatly. I believe that cancer must be attacked from multiple angles to truly 
make advancements in stopping the loss of life to this disease. The organometallic anticancer 
drugs that have been used over the past few decades have worked well, but cancers are appearing 
that are resistant to treatment from drugs such as cisplatin. Other treatments will be required. 
While nanoparticles are most likely not the complete answer to the problem, they are being used 
as anticancer therapies that can treat cancers that are resistant to cisplatin.29 Immunotherapy has 
become a promising treatment method as well, but there are still various issues with this route. 
Nanoparticles have been developed to help increase immune responses to assist the body in 
fighting the cancer and overcome some of the barriers faced by immunotherapy.30 Radiation is 
another common cancer treatment. The major issue associated with radiation is that healthy cells 
around the tumors become damaged from the treatment. Scientists have developed nanoparticles 
that are able to be used for radiotherapy that assist in limiting the damage done to nearby cells.31 
Nanoparticles are able to overcome many of the issues that face current treatment methods and 
they offer other possible uses in the cancer field. 
One of the major issues with cancer treatments involves being able to detect the cancer in 
time. If the cancer is caught at an earlier stage, a patient has a higher likelihood of survival. 
Cancer can often go undetected, even by some of our best imaging processes. The imaging 
process needs to continue to expand and advance. Nanoparticles can be used for this as well. One 
advantage that nanoparticles exhibit is the ability to be used for multimodal imaging.16,32 
Nanoparticles similar to the UCNP may be the imaging system that allows doctors to detect 
cancer earlier in patients as they offer multiple methods for visualizing of tumors. The ability of 
nanoparticles to congregate within tumor tissue allows for increased imaging accuracy as well. 
The size of nanoparticles can be controlled to make them fit into the openings of cancerous cells, 
but they are too large to fit into regular cells. This leads to specific uptake of the particles by 
tumor tissue. If the nanoparticles are created with compounds that create good contrast agents, 
then imaging can be utilized where only the tumor tissue will be seen. 
The use of nanoparticles in cancer imaging, prevention and treatment is growing. The 
possible combinations to make use of seem to provide an endless number of uses to be found. 
Preventing patients from developing cancer seems like a possibility from the use of 
nanoparticles. If patients do develop cancer, then nanoparticles may be a significant method to 
visualize and treat the cancer. The field of nanomedicine will continue to grow and develop. 
Nanoparticles will be part of the answer to helping prevent more deaths from cancer, but they are 
not the final answer. Cancer is an extremely broad set of diseases. With all of the varying types 
of cancer, the number of treatments or cures will need to vary just as much. Nanoparticles offer 
the ability to be modified in ways that allow them to be used for imaging, prevention and 
treatment of cancer that can hopefully be used to match the variety found within this disease. The 
future applications of nanoparticles within this field will continue to grow and may be an 
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